These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. [Cardiovascular risks of oral contraceptives: dose-response relationship]. Kelleher CC. Contracept Fertil Sex (Paris); 1991 Apr; 19(4):285-8. PubMed ID: 12343220 [Abstract] [Full Text] [Related]
23. [Oral contraception: evolution of concepts over the last thirty years]. Belaisch J, Hommais-loufrani B. Contracept Fertil Sex (Paris); 1987 Nov; 15(11 Suppl):1-8. PubMed ID: 12281408 [Abstract] [Full Text] [Related]
24. [Metabolic risks of oral contraception]. Monier L. Rev Int Pediatr; 1988 Feb; (178):64-5. PubMed ID: 12282576 [Abstract] [Full Text] [Related]
25. [Combined estrogen-progestagen contraception and glucid and water-sodium metabolism]. Belaisch J, Hommais-loufrani B. Contracept Fertil Sex (Paris); 1988 Feb; 16(2):3-7. PubMed ID: 12342001 [Abstract] [Full Text] [Related]
26. Researchers can now investigate long-term effects of OCs on cancer. Rubin GL, Peterson HB. Contracept Technol Update; 1985 Jan; 6(1):7-12. PubMed ID: 12279918 [Abstract] [Full Text] [Related]
28. [Pros and cons of triphasic oral contraception]. Berdah J. Contracept Fertil Sex (Paris); 1985 Dec; 13(12):1205-10. PubMed ID: 12267512 [Abstract] [Full Text] [Related]
29. [Contraception at risk]. Dubois C, Le Strat N. Rev Prat; 1987 Sep 21; 37(38):2293-301. PubMed ID: 3659796 [Abstract] [Full Text] [Related]
30. Combined progestin and estrogen (oral), and other forms of hormonal contraception. McPherson K. Curr Opin Obstet Gynecol; 1991 Aug 21; 3(4):486-90. PubMed ID: 1878505 [Abstract] [Full Text] [Related]
31. Depo Provera. Position paper on clinical use, effectiveness and side effects. Bigrigg A, Evans M, Gbolade B, Newton J, Pollard L, Szarewski A, Thomas C, Walling M. Br J Fam Plann; 1999 Jul 21; 25(2):69-76. PubMed ID: 10454658 [Abstract] [Full Text] [Related]
32. [Cutaneous effects in hormonal contraception]. Thomas P, Dalle E, Revillon B, Delecour M, Devarenne-nicolle MF, Pagniez I. NPN Med; 1985 Jan 01; 5(81):19-24. PubMed ID: 12281276 [Abstract] [Full Text] [Related]
33. [Contraception without risk of breast disease: epidemiologic and physiopathologic arguments]. Le Coutour X. NPN Med; 1985 Apr 02; 5(88):471-6. PubMed ID: 12315304 [Abstract] [Full Text] [Related]
34. [Oral contraception and carbohydrate metabolism: III--practical implications]. Hilal M. Contracept Fertil Sex (Paris); 1986 Jan 02; 14(1):59-62. PubMed ID: 12341242 [Abstract] [Full Text] [Related]
35. [Post-coital contraception]. Serfaty D. Contracept Fertil Sex (Paris); 1985 Jan 02; 13(1 Suppl):359-64. PubMed ID: 12280207 [Abstract] [Full Text] [Related]
36. Modern trends in contraception. Burkman RT. Obstet Gynecol Clin North Am; 1990 Dec 02; 17(4):759-74. PubMed ID: 2128711 [Abstract] [Full Text] [Related]
37. Pharmacodynamic effects of oral contraceptive steroids on biochemical markers for arterial thrombosis. Studies in non-diabetic women and in women with insulin-dependent diabetes mellitus. Petersen KR. Dan Med Bull; 2002 Feb 02; 49(1):43-60. PubMed ID: 11894723 [Abstract] [Full Text] [Related]
38. Oral contraceptive risks: a realistic appraisal. Bressler R, Durand JL. Drug Ther (NY); 1979 Oct 02; 9(10):81-95. PubMed ID: 12279276 [Abstract] [Full Text] [Related]
39. Hormonal contraception and cancer. Drife J, Guillebaud J. Br J Hosp Med; 1986 Jan 02; 35(1):25-9. PubMed ID: 3955285 [Abstract] [Full Text] [Related]